Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1394results about How to "Toxic reduction" patented technology

Treatment of biomass to obtain fermentable sugars

Biomass is pretreated using a low concentration of aqueous ammonia at high biomass concentration. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation.
Owner:ALLIANCE FOR SUSTAINABLE ENERGY +1

Desalination methods and systems that include carbonate compound precipitation

Desalination methods that include carbonate compound precipitation are provided. In certain embodiments, feed water is subjected to carbonate compound precipitation conditions prior to desalination. In certain embodiments, desalination waste brine is subjected to carbonate compound precipitation conditions. In yet other embodiments, both feed water and waste brine are subjected to carbonate compound precipitation conditions. Aspects of embodiments of the invention include carbone dioxide sequestration. Embodiments of the invention further employ a precipitate product of the carbonate compound precipitation conditions as a building material, e.g., a cement. Also provided are systems configured for use in methods of the invention.
Owner:ARELAC INC

Treatment of biomass to obtain ethanol

Ethanol was produced using biocatalysts that are able to ferment sugars derived from treated biomass. Sugars were obtained by pretreating biomass under conditions of high solids and low ammonia concentration, followed by saccharification.
Owner:ALLIANCE FOR SUSTAINABLE ENERGY +1

IL-2 selective agonists and antagonists

The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
Owner:AICURIS GMBH & CO KG

Compositions and methods for treatment of viral diseases

InactiveUS20100009970A1Slow and stop replicationReduce loadBiocideNervous disorderSingle-Stranded RNADisease
The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.
Owner:EXCRX SINGAPORE PTE +1

Combination therapy for the treatment of immunoinflammatory disorders

The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and a Group A enhancer (e.g., antifungal agent, antigout agent, anti-infective agent, antiprotozoal agent, antiviral agent, humectant, sunscreen, vitamin D compound, microtubuline inhibitor, or zinc salt) or analog or metabolite thereof to the patient. The invention also features a pharmaceutical composition containing an NsIDI and Group A enhancer or analog or metabolite thereof for the treatment or prevention of an immunoinflammatory disorder.
Owner:ZALICUS INC

Conjugates comprising a biodegradable polymer and uses therefor

Biologically active agents covalently linked to a polymer. The polymer is preferably a biodegradable polymer are provided. The biologically active agent is preferably a protein, such as an extracellular soluble protein, e.g., an extracellular enzyme. The enzyme can be an apyrase, e.g., NTPDase. Conjugates of the invention can be used as therapeutics in subjects. For example, a conjugate comprising an apyrase can be used for treating and preventing thrombosis, atherosclerotic plaque complications and vascular disorders.
Owner:MERSANA THERAPEUTICS INC +1

Teeth whitening compositions and methods

InactiveUS20100266989A1Less toxicEffective sensitivityCosmetic preparationsBiocideEosin BErythrosine B
Disclosed herein are teeth whitening compositions generally including an oxidizing agent (e.g., a peroxide), and an activating agent that has an emission wavelength between about 400 nm and about 570 nm (e.g., Eosin B, Eosin Y, or Erythrosine B). Methods of employing these compositions to whiten teeth, methods of making these compositions and kits that include some or part of the composition ingredients, are also described.
Owner:KLOX TECH

Self healing composite material and method of manufacturing same

A self-healing material comprises a matrix embedded with micro-pockets of a healing-agent releasable by a crack in the matrix. The healing-agent is able to bond to the matrix to repair the crack. The healing-agent is contained in microcapsules. A corresponding catalyst for the healing-agent is embedded in the matrix and contained in a plurality of microcapsules as an emulsion. The emulsion comprises an oil, a perfluorated solvent, a hydrophobic ionic liquid, or mixtures thereof. A method of manufacturing the self-healing material comprises the steps of identifying an operational temperature range of the material, providing at least one substance as the healing-agent, which substance remaining substantially in a liquid state within the operational temperature range, identifying an operational evaporation rate of the healing-agent and providing the substance with a curing time according to the evaporation rate.
Owner:MPB COMM +1

Novel compounds with high therapeutic index

ActiveUS20060241017A1Improve bioavailability and efficacyLess toxicBiocideAntipyreticAmino acid compositionCompound (substance)
The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.
Owner:SIGNATURE R & D HLDG LLC

Desalination methods and systems that include carbonate compound precipitation

Desalination methods that include carbonate compound precipitation are provided. In certain embodiments, feed water is subjected to carbonate compound precipitation conditions prior to desalination. In certain embodiments, desalination waste brine is subjected to carbonate compound precipitation conditions. In yet other embodiments, both feed water and waste brine are subjected to carbonate compound precipitation conditions. Aspects of embodiments of the invention include carbon dioxide sequestration. Embodiments of the invention further employ a precipitate product of the carbonate compound precipitation conditions as a building material, e.g., a cement. Also provided are systems configured for use in methods of the invention.
Owner:CALERA CORP

Controlling plant pathogens with bacterial/fungal antagonist combinations

Fungal / bacterial antagonist combinations, a seed coated with one of the combinations and a plant protected from plant pathogens by one of the combinations. The invention is also a fungal / bacterial antagonist combination comprising a Trichoderma virens fungal antagonist and a Bacillus subtilis var. amyloliquefaciens (Bacillus amyloliquefaciens) bacterial antagonist and its use for controlling plant pathogens as a biocontrol agent, bio-pesticide or bio-fungicide. The invention also finds utility as a fungal / bacterial antagonist combination applied to the seed, stalk or leaf that results in an increase in plant yield. Control of early and late season stalk and root rot caused by fungi such as Fusarium, Phythium, Phytophthora and Penicillium in tomatoes, peppers, turf grass, soybeans, sunflower, wheat and corn is achieved.
Owner:NOVOZYMES BIOAG AS

Methods and reagents for the treatment of immunoinflammatory disorders

InactiveUS20050192261A1Great efficacyMore treatment satisfactionBiocideNervous disorderDrugAntihistamine
The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient an antihistamine, either alone or in combination with one or more additional agents. The invention also features a pharmaceutical composition containing an antihistamine in combination with one or more additional agents.
Owner:COMBINATORX

Method and structure for adhesion of absorber material for thin film photovoltaic cell

A method for forming a thin film photovoltaic device includes providing a transparent substrate comprising a surface region and forming a first electrode layer overlying the surface region. The method further includes forming a thin layer of copper gallium material overlying the first electrode layer to act as an intermediary adhesive layer to facilitate attachment to the first electrode layer. Additionally, the method includes forming a copper layer overlying the thin layer and forming an indium layer overlying the copper layer to form a multilayered structure and subjecting the multilayered structure to thermal treatment process with sulfur bearing species to form a copper indium disulfide alloy material. The copper indium disulfide alloy material comprises a copper:indium atomic ratio of about 1.2:1 to about 3.0:1 overlying a copper gallium disulfide material converted from the thin layer. Furthermore, the method includes forming a window layer overlying the copper indium disulfide alloy material.
Owner:CM MFG

Polymeric antioxidants

Antioxidant polymers of the present invention comprise repeat units that include one or both of Structural Formulas (I) and (II):wherein:R is —H or a substituted or unsubstituted alkyl, acyl or aryl group;Ring A is substituted with at least one tert-butyl group or substituted or unsubstituted n-alkoxycarbonyl group;Ring B is substituted with at least one —H and at least one tert-butyl group or substituted or unsubstituted n-alkoxycarbonyl group;Rings A and B are each optionally substituted with one or more groups selected from the group consisting of —OH, —NH, —SH, a substituted or unsubstituted alkyl or aryl group, and a substituted or unsubstituted alkoxycarbonyl group;n is an integer equal to or greater than 2; andp is an integer equal to or greater than 0.The invention also includes methods of using and preparing these polymers.
Owner:UNIVERSITY OF MASSACHUSETTS LOWELL +1

Desalination methods and systems that include carbonate compound precipitation

Desalination methods that include carbonate compound precipitation are provided. In certain embodiments, feed water is subjected to carbonate compound precipitation conditions prior to desalination. In certain embodiments, desalination waste brine is subjected to carbonate compound precipitation conditions. In yet other embodiments, both feed water and waste brine are subjected to carbonate compound precipitation conditions. Aspects of embodiments of the invention include carbone dioxide sequestration. Embodiments of the invention further employ a precipitate product of the carbonate compound precipitation conditions as a building material, e.g., a cement. Also provided are systems configured for use in methods of the invention.
Owner:ARELAC INC

Operation mode and apparatus of short distance nitration-anaerobic ammoxidation batched biomembrane denitrogenation

InactiveCN1927739AToxic reductionControl the maximum cumulative concentrationTreatment with aerobic and anaerobic processesSludgeElectron donor
One kind of short range nitrifying-anaerobic aminoxidizing sequencing batch type denitrifying biomembrane mode and plant is disclosed. The limited aerating mode with real-time control of the sewage temperature inside the reactor and high frequency alternation between aeration and anaeration can inhibit the growth of nitrite oxidizing bacteria and denitrifying bacteria so that the aminoxidizing bacteria and the anaerobic aminoxidizing bacteria become the dominant bacteria in the nitrifying and denitrifying stages. In the nitrifying stage, nitrification is stopped in the nitrite step; and in the denitrifying stage, ammonia nitrogen acts as the direct electron donor to reduce nitrite. The plant is provided with fixed spherical composite stuffing with spherical shell of polypropylene and filled inside biological composite material. Sectional discrete water feeding mode is adopted to feed the sewage to be treated in four stages into the reactor.
Owner:HUNAN UNIV

Pharmaceutical compositions and methods to vaccinate against candidiasis

A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
Owner:LOS ANGELES BIOMEDICAL RES INST AT UCLA HARBOR MEDICAL CENT +1

Marine antifouling coating compositions

Disclosed are marine coating compositions that are useful to inhibit the fouling of a marine structure by a broad spectrum of organisms. Generally, the marine coating composition comprises an antifouling agent and an organic vehicle.
Owner:NOVUS INTERNATIONAL INC

Post-coupling synthetic approach for polymeric antioxidants

A method of preparing an antioxidant polymer includes forming or obtaining a first polymer having reactive pendant groups, where the first polymer does not include cyclic anhydride repeat units, and derivatizing the first polymer with an antioxidant. Another method of preparing an antioxidant polymer includes forming or obtaining a first polymer having reactive pendant groups and derivatizing the first polymer with an antioxidant, where the antioxidant is attached to the first polymer by an acetal, amide, amine, carbamate, carbonate, ester, ether or thioether linkage or by a carbon-carbon bond. The invention is also directed to polymers that are generally prepared by these methods, compositions that include such polymers and methods of using such polymers.
Owner:UNIVERSITY OF MASSACHUSETTS LOWELL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products